

CALQUENCE® CONFIDENCE

RISK REDUCTION IN DISEASE
PROGRESSION OR DEATH

PROVEN

5-YEAR

DATA¹

Reference: 1. Sharman J, Egged M, Jurczak W, et al. Acalabrutinib + obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Abx 7529 with supplemental information.

CALQUENCE® is a registered trademark of the AstraZeneca group of companies.
©2022 AstraZeneca. All rights reserved.
For healthcare professionals only.



Scan the QR code to access the full Calquence Prescribing Information

AstraZeneca 

AstraZeneca Singapore Pte Ltd
10 Kallang Avenue #12-10,
Japara Tower 2, Singapore 339110
Tel: +65 6 812 6700 Fax: +65 6 355 3050
SG-4552 Date of Approval: 28/06/2022


CALQUENCE
acalabrutinib 100 mg tablets